Artikel ; Online: The 4
Pediatric rheumatology online journal
2024 Band 21, Heft Suppl 1, Seite(n) 79
Abstract: Since IL-18 has recently emerged as a biomarker associated with refractory disease course in SJIA, the focus of the discussion was the feasibility of the biomarker-driven drug development to SJIA. Overall, there was broad agreement on the conclusion that ...
Abstract | Since IL-18 has recently emerged as a biomarker associated with refractory disease course in SJIA, the focus of the discussion was the feasibility of the biomarker-driven drug development to SJIA. Overall, there was broad agreement on the conclusion that IL-18 is a uniquely specific biomarker for many of the subsets of SJIA most in need of new therapies, and it may define a class of diseases mediated by IL-18 excess. The consensus was that leveraging IL-18 remains our most promising "lead" for use in refractory SJIA as it may mechanistically explain the disease pathophysiology and lead to more targeted therapies. |
---|---|
Mesh-Begriff(e) | Humans ; Arthritis, Juvenile/drug therapy ; Interleukin-18 ; Consensus ; Disease Progression ; Biomarkers |
Chemische Substanzen | Interleukin-18 ; Biomarkers |
Sprache | Englisch |
Erscheinungsdatum | 2024-01-05 |
Erscheinungsland | England |
Dokumenttyp | Journal Article |
ZDB-ID | 2279468-2 |
ISSN | 1546-0096 ; 1546-0096 |
ISSN (online) | 1546-0096 |
ISSN | 1546-0096 |
DOI | 10.1186/s12969-023-00867-y |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.